Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, Takechiyo Yamada
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	head and neck squamous cell carcinoma cetuximab paclitaxel immune checkpoint inhibitor chemotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8a00537999744e5cb5cbfd781833e46f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a00537999744e5cb5cbfd781833e46f
record_format	dspace
spelling	oai:doaj.org-article:8a00537999744e5cb5cbfd781833e46f2021-11-25T18:18:06ZClinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma10.3390/medicina571111511648-91441010-660Xhttps://doaj.org/article/8a00537999744e5cb5cbfd781833e46f2021-10-01T00:00:00Zhttps://www.mdpi.com/1648-9144/57/11/1151https://doaj.org/toc/1010-660Xhttps://doaj.org/toc/1648-9144<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This study aimed to evaluate the efficacy and safety of chemotherapy after immune checkpoint inhibitor administration in recurrent metastatic head and neck cancer by focusing on a single regimen. <i>Materials and Methods</i>: We retrospectively reviewed clinical and radiological data from the medical records of 18 patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab and paclitaxel (Cmab + PTX) after progression following immune checkpoint inhibitor (ICI) therapy. The objective response rate (ORR) and disease control rate (DCR) were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Adverse events (AEs) were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. <i>Results</i>: In all patients, the ORR, DCR, median PFS, and median OS were 44.4%, 72.2%, 3.8 months, and 9.6 months, respectively. Regarding AEs, three patients developed grade 3 neutropenia. Grade 3 anemia, paronychia, asthenia, and peripheral neuropathy were observed in one patient each. There were no treatment-related deaths. <i>Conclusions</i>: Cmab + PTX was shown to maintain high efficacy and acceptable safety for R/M HNSCC that progressed after ICI therapy. Further research is needed to establish optimal treatment sequences and drug combinations for recurrent R/M HNSCC.Shinsuke SuzukiSatoshi ToyomaYohei KawasakiKoh KoizumiNobuko IikawaKazuhiro ShiinaTentaro EndoTomoe AbeTeppei KougaTakechiyo YamadaMDPI AGarticlehead and neck squamous cell carcinomacetuximabpaclitaxelimmune checkpoint inhibitorchemotherapyMedicine (General)R5-920ENMedicina, Vol 57, Iss 1151, p 1151 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	head and neck squamous cell carcinoma cetuximab paclitaxel immune checkpoint inhibitor chemotherapy Medicine (General) R5-920
spellingShingle	head and neck squamous cell carcinoma cetuximab paclitaxel immune checkpoint inhibitor chemotherapy Medicine (General) R5-920 Shinsuke Suzuki Satoshi Toyoma Yohei Kawasaki Koh Koizumi Nobuko Iikawa Kazuhiro Shiina Tentaro Endo Tomoe Abe Teppei Kouga Takechiyo Yamada Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
description	<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This study aimed to evaluate the efficacy and safety of chemotherapy after immune checkpoint inhibitor administration in recurrent metastatic head and neck cancer by focusing on a single regimen. <i>Materials and Methods</i>: We retrospectively reviewed clinical and radiological data from the medical records of 18 patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab and paclitaxel (Cmab + PTX) after progression following immune checkpoint inhibitor (ICI) therapy. The objective response rate (ORR) and disease control rate (DCR) were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Adverse events (AEs) were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. <i>Results</i>: In all patients, the ORR, DCR, median PFS, and median OS were 44.4%, 72.2%, 3.8 months, and 9.6 months, respectively. Regarding AEs, three patients developed grade 3 neutropenia. Grade 3 anemia, paronychia, asthenia, and peripheral neuropathy were observed in one patient each. There were no treatment-related deaths. <i>Conclusions</i>: Cmab + PTX was shown to maintain high efficacy and acceptable safety for R/M HNSCC that progressed after ICI therapy. Further research is needed to establish optimal treatment sequences and drug combinations for recurrent R/M HNSCC.
format	article
author	Shinsuke Suzuki Satoshi Toyoma Yohei Kawasaki Koh Koizumi Nobuko Iikawa Kazuhiro Shiina Tentaro Endo Tomoe Abe Teppei Kouga Takechiyo Yamada
author_facet	Shinsuke Suzuki Satoshi Toyoma Yohei Kawasaki Koh Koizumi Nobuko Iikawa Kazuhiro Shiina Tentaro Endo Tomoe Abe Teppei Kouga Takechiyo Yamada
author_sort	Shinsuke Suzuki
title	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_short	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_full	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_fullStr	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_full_unstemmed	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_sort	clinical outcomes of cetuximab and paclitaxel after progression on immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8a00537999744e5cb5cbfd781833e46f
work_keys_str_mv	AT shinsukesuzuki clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT satoshitoyoma clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT yoheikawasaki clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT kohkoizumi clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT nobukoiikawa clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT kazuhiroshiina clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT tentaroendo clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT tomoeabe clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT teppeikouga clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma AT takechiyoyamada clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
_version_	1718411394001403904

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ejemplares similares